DFDA

Valsartan (ARB)

Treatment for Hypertensive Heart Disease

Typical Dosage: 40mg - 320mg daily

Effectiveness
87%
Safety Score
70%
Clinical Trials
2
Participants
500K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
40mg - 320mg daily
Time to Effect
2-4 weeks for full BP effect, months for cardiac remodeling
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
18(Treat 18 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
40(Treat 40 patients to see 1 additional serious adverse event)
Confidence Score
93%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$300
Side Effect Mgmt:$75
Total Annual:$475
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$25,000/QALY
QALYs Gained
2.4
Outcome-Based Costs
Cost per Responder
$659.72
Comparison vs Lisinopril (ACE Inhibitor)
Cost Difference
+$70/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Valsartan (ARB) Outcomes

for Hypertensive Heart Disease

Efficacy Outcomes
Overall Effectiveness
+87%
Response Rate
+72%
Common Side Effects
Dizziness
+5%
Hyperkalemia
+4%
Angioedema
+0.1%

Sources:

nih.gov
nih.gov
elsevierpure.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
2 active trials recruiting for Valsartan (ARB) in Hypertensive Heart Disease

Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

NCT05498675RECRUITING
View Study
180 participants
OBSERVATIONAL
Beijing, China
Started: Sep 1, 2021

An Investigator-initiated, Prospective, Open-label, Multicenter Randomized Controlled Trial, Comparing the Efficacy of Sacubitril/Valsartan and Standard Treatment on Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients Without Hypertensive

NCT07910058NOT YET RECRUITINGPHASE4
View Study
472 participants
INTERVENTIONAL
Started: Oct 31, 2026
Completed Clinical Trials
1 completed trial for Valsartan (ARB) in Hypertensive Heart Disease

Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance

NCT00129233COMPLETEDPHASE4
View Study
1.15K participants
INTERVENTIONAL
Nagoya, Japan
Started: Oct 1, 2004